BioCryst Pharmaceuticals Has Completed Negotiations With The Pan-Canadian Pharmaceutical Alliance For Orladeyo (Berotralstat), Which Is Approved In Canada For The Routine Prevention Of Attacks Of Hereditary Angioedema For Patients 12 Years Of Age And Older
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals has successfully completed negotiations with the Pan-Canadian Pharmaceutical Alliance for Orladeyo, a drug approved in Canada for preventing hereditary angioedema attacks in patients aged 12 and older.
September 17, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals has completed negotiations with the Pan-Canadian Pharmaceutical Alliance for Orladeyo, potentially boosting its market presence and sales in Canada.
The completion of negotiations with the Pan-Canadian Pharmaceutical Alliance for Orladeyo suggests a positive development for BioCryst Pharmaceuticals, as it may lead to increased sales and market penetration in Canada. This is likely to have a positive short-term impact on BCRX's stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90